Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage III Bladder Cancer AJCC v8: early-phase trial registry
4 of 7 indexed Stage III Bladder Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #2,497 of 28,707 conditions by registered trial count.
7 US clinical trials · 4 currently recruiting · #2,497 of 28,707 conditions by registered trial count
Stage III Bladder Cancer AJCC v8: 7 US clinical trials tracked, 4 recruiting.
Stage III Bladder Cancer AJCC v8 is the subject of 7 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 4 of these trials.
Enrollment posture brief
Registry condition stage-iii-bladder-cancer-ajcc-v8
OPEN 4 | RECR 57% | LATE 2 | EARLY 4 | RANK #2497 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adverse Childhood Experiences (57% recruiting · 14 trials)
Stage III Bladder Cancer AJCC v8 lists 4 open slots (57% of 7 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage III Bladder Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage III Bladder Cancer AJCC v8 is recruiting above its size-band peers.
4 of 7 indexed trials (57.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage III Bladder Cancer AJCC v8 research.
National Cancer Institute (NCI) accounts for 4 of 7 trials (57.1%). 4 distinct sponsors appear on at least one study for this condition label.
-
Most Stage III Bladder Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 75 among the 7 trials that report a genuine target (sentinel values excluded). 5 of those (71.4%) plan for fewer than 100 participants.
-
Stage III Bladder Cancer AJCC v8 research is mostly interventional.
7 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
7 total, page 1 of 1
An Education and Navigation Support Tool to Improve Participation in Care Coordination Among Patients With Locally Advanced, Metastatic and Unresectable Bladder Cancer and Their Caregivers
Roswell Park Cancer Institute
NCT06414317
Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Mayo Clinic
NCT06764095
Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes
National Cancer Institute (NCI)
NCT03375307
Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
Emory University
NCT05756569
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study
National Cancer Institute (NCI)
NCT05092958
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
NCT04216290
Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma
National Cancer Institute (NCI)
NCT03854474
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 3 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage III Bladder Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage III Bladder Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage III Bladder Cancer AJCC v8 page
7 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Stage III Bladder Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Stage III Bladder Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Bladder Cancer AJCC v8 condition card totals 7 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.